CytomX Therapeutics, Inc. $CTMX Shares Bought by Baker BROS. Advisors LP

Baker BROS. Advisors LP raised its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 22.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 4,250,826 shares of the biotechnology company’s stock after buying an additional 766,600 shares during the period. Baker BROS. Advisors LP owned about 2.51% of CytomX Therapeutics worth $13,560,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Orbimed Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the second quarter worth about $19,208,000. Commodore Capital LP purchased a new position in CytomX Therapeutics during the second quarter valued at approximately $17,462,000. Perceptive Advisors LLC acquired a new position in CytomX Therapeutics in the second quarter valued at approximately $15,876,000. Franklin Resources Inc. purchased a new stake in CytomX Therapeutics in the 2nd quarter worth approximately $13,096,000. Finally, Vivo Capital LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter worth approximately $13,096,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Stock Down 3.9%

CTMX opened at $4.68 on Friday. The firm’s fifty day simple moving average is $5.19 and its two-hundred day simple moving average is $4.02. CytomX Therapeutics, Inc. has a 52-week low of $0.40 and a 52-week high of $6.35. The company has a market cap of $792.93 million, a price-to-earnings ratio of 11.70 and a beta of 2.44.

Analyst Upgrades and Downgrades

CTMX has been the subject of several recent research reports. Barclays lifted their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of CytomX Therapeutics in a report on Monday, March 9th. Cantor Fitzgerald raised their price target on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Finally, Piper Sandler lifted their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, CytomX Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $9.00.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.